Serial magnetic resonance imaging in multiple sclerosis: Correlation with attacks, disability, and disease stage

Journal of Neuroimmunology

Volumn 104, Issue 2, 2000, Pages 164-173

  Weiner, Howard L ^a   Guttmann, Charles R G ^b   Khoury, Samia J ^a   Orav, E John ^b   Hohol, Marika J ^a   Kikinis, Ron ^b   Jolesz, Ferenc A ^b  

^a Center for Neurological Imaging Partners Multiple Sclerosis Center   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Disability; MRI; Multiple sclerosis; Natural history

Indexed keywords

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRIORITY JOURNAL;

ADULT; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEVERITY OF ILLNESS INDEX;

EID: 0034193963     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00273-8     Document Type: Article

References (47)

1. Arnold D.L., Riess G.T., et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann. Neurol. 36:1994;76-82.
2. Barkhof F., Scheltens P., et al. Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs. clinical findings in determining disease activity. Am. J. Roentgenol. 159:1992;1041-1047.
3. Bastianello S., Pozzilli C., et al. Serial study of gadolinium-DTPA MRI enhancement in multiple sclerosis. Neurology. 40:1990;591-595.
4. Davie C.A., Hawkins C.P., et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain. 117:1994;49-58.
5. Diggle P.J., Liang K.-Y., et al. Analysis of Longitudinal Data. 1994;Oxford Science, Oxford.
6. Durelli L., Bongioanni M.R., et al. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate. MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 44:(3):1994;406-413.
7. Filippi M., Paty D.W., et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 45:1995;255-260.
8. Gonzalez-Scarano F., Grossman R.I., et al. Multiple sclerosis disease activity correlates with gadolinium-enhanced magnetic resonance imaging. Ann. Neurol. 21:1987;300-306.
9. Grossman R.I., Gonzalez-Scarano F., et al. Multiple sclerosis: Gadolinium enhancement in MR imaging. Radiology. 161:1986;721-725.
10. Grossman R.I., Braffman B.H., et al. Multiple sclerosis: serial study of gadolinium-enhanced MR imaging. Radiology. 169:1988;117-122.
11. Guttmann C.R.G., Ahn S.S., et al. The evolution of multiple sclerosis lesions on serial MRI. Am. J. Neuroradiol. 16:1995;1481-1491.
12. Guttmann C.R.G., Jolesz F.A., et al. White matter changes with normal aging. Neurology. 50:1998;972-978.
13. Guttmann C.R.G., Kikinis R., et al. Quantitative follow-up of patients with multiple sclerosis using MRI: reproducibility. J. Magn. Reson. Imag. 9:1999;509-518.
14. Harris J.O., Frank J.A., et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann. Neurol. 29:1991;548-555.
15. Hauser S.L., Dawson D.M., et al. Intensive immunosuppression in progressive multiple sclerosis: A randomized, three-arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH. N. Engl. J. Med. 308:1983;173-180.
16. Hohol M.J., Guttmann C.R.G., et al. Serial neuropsychological assessment and MRI analysis in multiple sclerosis. Ann. Neurol. 54:1997;1018-1025.
17. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology. 43:1993;655-661.
18. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology. 45:1995;1277-1285.
19. Issac C., Li D.K., et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology. 38:1988;1511-1515.
20. Jacobs L.D., Cookfair D.L., et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 39:1996;285-294.
21. Kappos L., Moeri D., et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and change in disability or impairment in multiple sclerosis: a meta-analysis. Lancet. 353:1999;964-969.
22. Kastrukoff L.F., Oger J.J., et al. Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation. Neurology. 40:1990;479-486.
23. Khoury S.J., Guttman C.R.G., et al. Longitudinal MRI imaging in multiple sclerosis: correlation between disability and lesion burden. Neurology. 44:1994;2120-2124.
24. Khoury S.J., Orav E.J., et al. Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 53:1999;758-764.
25. Khoury, S.J., Guttmann, C.R.G., Orav, E.J., Hohol, M.J., Kikinis, R., Jolesz, F.A., Hafler, D.A., Weiner, H.L. Changes in activated cells in the block correlate with disease activity in multiple sclerosis. Ann. Neurol., in press.
26. Kikinis R., Guttmann C.R., et al. Quantitative follow-up of patients with multiple sclerosis using MRI: technical aspects. J. Magn. Reson. Imag. 9:1999;519-530.
27. Kikinis R., Shenton M.E., et al. Routine quantitative analysis of brain and cerebrospinal fluid spaces with MR imaging. J. Magn. Reson. Imag. 2:1992;619-629.
28. Lai M., Hodgson T., et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 60:1996;339-341.
29. Lassmann H. Mechanisms of demyelination and tissue damage in multiple sclerosis. Acta Neurol. Belg. 99:1999;6-10.
30. Lublin F.D., Reingold S.C. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 46:1996;907-911.
31. Mammi S., Filippi M., et al. Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurol. Scand. 94:1996;93-96.
32. Martin R., McFarland H.F., et al. Immunological aspects of demyelinating diseases. Annu. Rev. Immunol. 10:1992;153-187.
33. McFarland M.F., Stone L.A., et al. MRI studies of multiple sclerosis: Implications for the natural history of the disease and for monitoring effectiveness of experimental therapies. Mult. Scler. 2:1996;198-205.
34. Metcalf D., Kikinis R., et al. IEEE-EMBS. 3:1992;945-946.
35. Miller D.H., Rudge P., et al. Serial gadolinium enhanced magnetic resonance imaging in multiple sclerosis. Brain. 112:1988;1057-1090.
36. Miller D.H., Grossman R.I., et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain. 121:1998;3-24.
37. Molyneux P.D., Filippi M., et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann. Neurol. 43:1998;332-339.
38. O'Riordan J.I., Thompson A.J., et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain. 121:1998;495-503.
39. Smith M.E., Stone L.A., et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann. Neurol. 33:1993;480-489.
40. Thompson A.J., Kermode A.G., et al. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. Br. Med. J. 300:1990;631-634.
41. Thompson A.J., Kermode A.G., et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann. Neurol. 29:1991;53-62.
42. Thompson A.J., Miller D., et al. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology. 42:1992;60-63.
43. 1 spin-echo MRI correlates with disease progression in multiple sclerosis. Neurology. 47:1996;1469-1476.
44. van Walderveen M.A., Barkhof F., et al. Correlating MR imaging and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short TR/TE ('T1-weighted') spin-echo images. Neurology. 45:1995;1684-1690.
45. Weinshenker B.G., Bass B., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain. 112:1989;133-146.
46. Wells W.M. III, Grimson W.E.L., et al. Adaptive segmentation of MRI data. IEEE Trans. Med. Imag. 15:1996;429-443.
47. Willoughby E.W., Grochowski E., et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann. Neurol. 25:1989;43-49.